LLY Sep 2024 640.000 call
| Previous close | 126.25 |
| Open | 126.25 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 640.00 |
| Expiry date | 2024-09-20 |
| Day's range | 126.25 - 126.25 |
| Contract range | N/A |
| Volume | |
| Open interest | 24 |
Yahoo FinanceNovo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
BloombergAmgen Soars as CEO Touts Experimental Obesity Drug’s Progress
(Bloomberg) -- Amgen Inc.’s shares soared after its chief executive officer said he was “very encouraged” by early results from a study of the company’s experimental obesity drug, MariTide. Most Read from BloombergSaudi Arabia Steps Up Arrests Of Those Attacking Israel OnlineApple Rallies on Upbeat Forecast, Record-Setting BuybackTurkey Confirms All Trade Halt With Israel Over War in GazaHuawei Secretly Backs US Research, Awarding Millions in PrizesTrump Auditions VP Picks Before Wealthy Donors
- Reuters
US STOCKS-Futures rise on Apple, Amgen boost; jobs data awaited
Futures tied to Wall Street's main indexes gained on Friday, lifted by upbeat corporate updates from Apple and Amgen, while traders braced for a key jobs report for a clearer outlook on the labor market and the interest rate path. Apple jumped 6.1%, outpacing other megacap stocks in premarket trading after the iPhone maker unveiled a record $110 billion share buyback program and beat modest expectations for quarterly results and forecast.
